TABLE 1.
Baseline participant characteristics.
| Characteristic | PK | Plasma biomarkers | iADRS and CDR‐SB |
|---|---|---|---|
| Treatment, n (%) | |||
| Donanemab | 177 | 111 (50.5) | 131 (51.2) |
| Placebo | 0 | 109 (49.5) | 125 (48.8) |
| Mean age, years (range) | 74.4 (54, 88) | 75.2 (61, 86) | 75.1 (61, 86) |
| Mean weight, kg (range) | 73.2 (40.3, 123) | 73.9 (42.7, 123.1) | 73.6 (42.7, 123.1) |
| Mean body mass index, kg/m2 (range) | 26.3 (15.9, 44.2) | 26.4 (15.9, 44.2) | 26.4 (15.9, 44.2) |
| Gender, n (%) | |||
| Men | 86 (48.6) | 109 (49.5) | 124 (48.4) |
| Women | 91 (51.4) | 111 (50.5) | 132 (51.6) |
| Race, n (%) | |||
| White | 153 (86.4) | 206 (93.6) | 242 (94.5) |
| Black | 7 (4.0) | 8 (3.6) | 8 (3.1) |
| Asian | 14 (7.9) | 3 (1.4) | 3 (1.2) |
| American Indian or Alaska Native | 2 (1.1) | 2 (0.9) | 2 (0.8) |
| Other | 1 (0.6) | 1 (0.5) | 1 (0.4) |
| Hispanic Origin, n (%) | 7 (4.0) | 7 (3.2) | 8 (3.1) |
| APOE ε4 Status | |||
| Carrier | 132 (74.6) | 153 (69.5) | 187 (73.0) |
| Noncarrier | 45 (25.6) | 66 (30.0) | 68 (26.6) |
| Unknown | 0 | 1 (0.5) | 1 (0.4) |
Abbreviations: APOE ε4, apolipoprotein E ε4 allele; CDR‐SB, Clinical Dementia Rating‐Sum of Boxes; iADRS, Integrated Alzheimer's Disease Rating Scale; n, number of participants; PK, pharmacokinetics.